AI Transformation Office (AITO)
Connecting value-chain experience to end-customer impact.
Most biopharma AI investment optimizes departments. The AITO optimizes the chain, treating the value chain as one connected experience, so that better internal handoffs show up as better outcomes for patients, physicians, hospitals, payers, and regulators.
The Outside-In Continuum. Work moves forward through the functions. Experience is felt at the outer ring, and what the outer ring reveals flows back to the hub to inform the next decision.
External outcomes are downstream of internal experience.
Patients, physicians, hospitals, and insurers judge a biopharma company by what reaches them: how quickly a therapy becomes available, how clearly evidence is communicated, how smoothly access works. Government entities judge it by the quality and consistency of what it submits and reports.
None of these experiences is created at the front line. Each is the downstream result of how R&D, Clinical, Manufacturing and Supply Chain, Commercial, and Medical Affairs hand work to one another.
The Pattern
Fragmented AI pilots, each deployed in isolation. Every function optimizes its own work, and no one examines how back-office efficiency changes the experience of patients, physicians, and other stakeholders at the front line.
The Move
Establish a dedicated AI Transformation Office that connects every link in the value chain, designing internal AI-enabled workflows to elevate external impact.
The Shift
From siloed automation to a unified, customer-centric value chain, coordinated by design so that each improvement compounds instead of colliding.
How the office works.
Connected Experience Mapping & Use Case Prioritization
Map AI opportunities across R&D, Clinical Development, Manufacturing and Supply Chain, Commercial, and Medical Affairs. Identify the friction points that degrade patient access or physician engagement, then prioritize the use cases that remove them first.
Internal “Customer Experience” (WX) Design
Design AI-enabled workflows and decision support for internal teams, treating each operational handoff with the same rigor of experience design usually reserved for external products. Adoption is designed in from the start, not requested afterward.
Cross-Functional Governance & Strategic Operating Model
Establish lightweight governance for how information, insight, and intellectual property move across functional boundaries, together with clear build-versus-buy decision rules, so that knowledge flows safely between departments.
Ecosystem Value Tracking & End-to-End Metrics
Measure AI success beyond cost reduction: value-chain velocity, internal adoption, speed of patient access, and health outcomes. Baselines and targets are set with the client, not assumed in advance.
An operating discipline, not a technology practice.
AI is new for every organization, including the firms that advise on it. What is not new is the work of standing up an office that gets a large biopharma organization to change.
Michael has done that repeatedly, including the change management office that kept dozens of concurrent R&D initiatives aligned under one methodology and, most recently, the design and set-up of an AI Transformation Office for a global biopharma company: its charter, workstream sub-charters, governance, reporting, operating rhythm, and roles.
Axioma sells no software and holds no technology partnerships. The advice is independent by design.
Every engagement starts with a conversation about the specific decision in front of you — not a standard proposal.
Start a Conversation